Curi RMB Capital LLC Has $860,000 Position in Viking Therapeutics, Inc. $VKTX

Key Points

• Curi RMB Capital LLC significantly increased its stake in Viking Therapeutics, acquiring a total of 35,599 shares, representing a 490.0% boost during the first quarter.
• Viking Therapeutics' stock performance has been mixed, with Wall Street analysts providing varying ratings; the average target price is set at $86.92.
• Insider trades have seen COO and CFO both sell shares, highlighting a 1.12% and 2.47% decrease in their ownership respectively, amidst broader insider selling activities.

Curi RMB Capital LLC grew its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 490.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 35,599 shares of the biotechnology company's stock after purchasing an additional 29,565 shares during the quarter. Curi RMB Capital LLC's holdings in Viking Therapeutics were worth $860,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in VKTX. Northern Trust Corp boosted its stake in Viking Therapeutics by 11.4% during the 4th quarter. Northern Trust Corp now owns 535,984 shares of the biotechnology company's stock valued at $21,568,000 after purchasing an additional 54,871 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of Viking Therapeutics by 228.5% during the fourth quarter. Ameriprise Financial Inc. now owns 1,479,596 shares of the biotechnology company's stock worth $59,540,000 after buying an additional 1,029,125 shares during the last quarter. Cetera Investment Advisers boosted its position in shares of Viking Therapeutics by 7.0% in the fourth quarter. Cetera Investment Advisers now owns 86,181 shares of the biotechnology company's stock valued at $3,468,000 after acquiring an additional 5,634 shares during the period. Frontier Capital Management Co. LLC grew its stake in shares of Viking Therapeutics by 2.8% in the fourth quarter. Frontier Capital Management Co. LLC now owns 597,739 shares of the biotechnology company's stock worth $24,053,000 after acquiring an additional 16,321 shares during the last quarter. Finally, FORA Capital LLC bought a new position in Viking Therapeutics during the fourth quarter worth $1,116,000. 76.03% of the stock is currently owned by institutional investors.

Viking Therapeutics Stock Down 0.5%

VKTX stock traded down $0.13 during midday trading on Thursday, reaching $25.74. The company's stock had a trading volume of 4,315,778 shares, compared to its average volume of 9,522,628. Viking Therapeutics, Inc. has a 52 week low of $18.92 and a 52 week high of $81.73. The business's 50-day simple moving average is $31.08 and its 200-day simple moving average is $28.23. The stock has a market cap of $2.89 billion, a PE ratio of -16.82 and a beta of 0.73.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.14). During the same quarter in the previous year, the business posted ($0.20) EPS. The business's quarterly revenue was up NaN% on a year-over-year basis. As a group, equities analysts forecast that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Insider Transactions at Viking Therapeutics

In other Viking Therapeutics news, CEO Brian Lian sold 26,889 shares of the business's stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $27.80, for a total transaction of $747,514.20. Following the sale, the chief executive officer directly owned 2,388,014 shares of the company's stock, valued at $66,386,789.20. The trade was a 1.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Greg Zante sold 4,266 shares of the stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $27.76, for a total value of $118,424.16. Following the transaction, the chief financial officer directly owned 168,660 shares of the company's stock, valued at $4,682,001.60. This trade represents a 2.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,421 shares of company stock valued at $984,405 over the last 90 days. 4.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on VKTX. HC Wainwright reissued a "buy" rating and issued a $102.00 price target on shares of Viking Therapeutics in a report on Tuesday, August 19th. Citigroup raised their price target on shares of Viking Therapeutics from $31.00 to $38.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Finally, Raymond James Financial dropped their target price on Viking Therapeutics from $125.00 to $122.00 and set a "strong-buy" rating for the company in a report on Thursday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $87.50.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.